Home  | About mdi |  Services  | Industries | News & Information | Partners | Contact| Site Map

February 24: Hanford Pharmaceuticals Issues a Nationwide Recall of Cefazolin for Injection Because of Possible Health Risk

Hanford Pharmaceuticals Inc., of Syracuse, NY, is voluntarily recalling four lots (379,975 vials) of Cefazolin for Injection, USP, 1 g/10 ml vials, an antibiotic used in a hospital environment. Certain lots of the active ingredient used to manufacture the product have been shown to contain microbial contamination (Bacillus pumilus, Staphylococcus hominis, Propionibacterium acnes, or Micrococcus luteus) which may pose a serious or life-threatening risk for some patients. Cefazolin for Injection, USP is used to treat skin and skin structure, respiratory and other infections.

The firm is notifying its customers and users of the recall by letter, and asking that they stop distribution, recall from their accounts, and request the return of the recalled lots. Hospitals, clinics, and users should stop using the affected lots immediately.

Check the lot numbers on the product label and promptly return any with the following lot numbers: Sandoz product - C4650, C4537; Watson product - C4689, C4665.

Patients who feel that they may have experienced an adverse reaction to recalled product should seek medical help. Patients or users can contact the firm at (315) 476-7418.

For complete FDA report of this update, please refer to following links: http://www.fda.gov/oc/po/firmrecalls/hanford02_06.html

If you have comments regarding this update, please email us at info@mdiconsultants.com

Home  | About mdi |  Services  | Industries | News & Information | Partners | Contact| Site Map